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Abstract
Objectives To quantify incremental effects of applying different criteria
to identify men who are candidates for drug treatment to prevent fracture
and to examine the extent to which fracture probabilities vary across
distinct categories of men defined by these criteria.
DesignCross sectional and longitudinal analysis of a prospective cohort
study.
Setting Multicenter Osteoporotic Fractures in Men (MrOS) study in the
United States.
Participants 5880 untreated community dwelling men aged 65 years
or over classified into four distinct groups: osteoporosis by World Health
Organization criteria alone; osteoporosis by National Osteoporosis
Foundation (NOF) but not WHO criteria; no osteoporosis but at high
fracture risk (at or above NOF derived FRAX intervention thresholds
recommended for US); and no osteoporosis and at low fracture risk
(below NOF derived FRAX intervention thresholds recommended for
US).
Main outcomemeasuresProportion of men identified for drug treatment;
predicted 10 year probabilities of hip and major osteoporotic fracture
calculated using FRAX algorithm with femoral neck bonemineral density;
observed 10 year probabilities for confirmed incident hip and major
osteoporotic (hip, clinical vertebral, wrist, or humerus) fracture events
calculated using cumulative incidence estimation, accounting for
competing risk of mortality.
Results 130 (2.2%) men were identified as having osteoporosis by using
the WHO definition, and an additional 422 were identified by applying
the NOF definition (total osteoporosis prevalence 9.4%). Application of
NOF derived FRAX intervention thresholds led to 936 (15.9%) additional
men without osteoporosis being identified as at high fracture risk, raising
the total prevalence of men potentially eligible for drug treatment to
25.3%. Observed 10 year hip fracture probabilities were 20.6% for men
with osteoporosis byWHO criteria alone, 6.8% for men with osteoporosis
by NOF (but not WHO) criteria, 6.4% for men without osteoporosis but
classified as at high fracture risk, and 1.5% for men without osteoporosis
and classified as at low fracture risk. A similar pattern was noted in
observed fracture probabilities for major osteoporotic fracture. Among
men with osteoporosis by WHO criteria, observed fracture probabilities
were greater than FRAX predicted probabilities (20.6% v 9.5% for hip
fracture and 30.0% v 17.4% for major osteoporotic fracture).
Conclusions and relevance Choice of definition of osteoporosis and
use of NOF derived FRAX intervention thresholds have major effects
on the proportion of older men identified as warranting drug treatment
to prevent fracture. Among men identified with osteoporosis by WHO
criteria, who comprised 2% of the study population, actual observed
fracture probabilities during 10 years of follow-up were highest and
exceeded FRAX predicted fracture probabilities. On the basis of findings
from randomized trials in women, these men are most likely to benefit
from treatment. Expanding indications for treatment beyond this small
group has uncertain value owing to lower observed fracture probabilities
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and uncertain benefits of treatment among men not selected on the
basis of WHO criteria.
Introduction
Older men experience 29% of the fractures among adults aged
50 years and older in the United States and account for 25% of
fracture related costs.1 Many of these fractures occur at sites
associated with low bone mineral density, increase in incidence
after age 50 years, and are considered to be related to
osteoporosis.2 3However, the best strategy to identify men who
are candidates for drug treatment to prevent fracture is uncertain,
in part because the cut-off value for bone mineral density to
identify osteoporosis is less well defined in men than in women.4
The diagnosis of osteoporosis in both men and women endorsed
by the World Health Organization is based on the cut-off value
of femoral neck bone mineral density used in women (T score
–2.5 or lower at the femoral neck, calculated using the young
white female normal reference database).5 6 In contrast, the
diagnosis of osteoporosis in men endorsed by the National
Osteoporosis Foundation (NOF)7 8 and adopted by some,9 but
not all,10 US professional societies is defined as a T score of
–2.5 or lower at the femoral neck, total hip, or lumbar spine,
calculated using the young white male normal reference base.
Use of the NOF’s definition increases the apparent prevalence
of osteoporosis in men, but controversy exists regarding whether
this effect is modest or substantial.11 12
Randomized trials in men have shown that drug treatment
increases bone mineral density,13-17 but the efficacy of drugs in
preventing clinical fracture events (that is, symptomatic fractures
coming to medical attention) in men is unknown. The efficacy
of drug treatment in reducing the risk of clinical fractures has
been demonstrated only in postmenopausal women with
osteoporosis defined by a female specific bone mineral density
T score of –2.5 or lower or with existing radiographic vertebral
fractures,18 with the exception of one randomized trial of
zoledronic acid in patients with recent hip fracture (75% of
whom were women, 42% with osteoporosis by WHO criteria)
that reported efficacy of treatment in reducing future fracture
events.19 Although osteoporosis by WHO criteria identifies
postmenopausal women who benefit from drug treatment to
lower the risk of clinical fractures, many postmenopausal women
and older men with bone mineral density T scores above –2.5
will subsequently experience clinical fracture events.20 This
common occurrence has prompted efforts to derive estimates
of the absolute risk of fracture for use in making decisions about
whether to recommend starting drug treatment in men, as well
as women.
The FRAX algorithm is a publicly available web based tool that
uses clinical risk factors and country specific data, with or
without consideration of femoral neck bone mineral density
measurement, to estimate an individual patient’s 10 year
probabilities of hip and major osteoporotic fractures (defined
by FRAX as clinical vertebral, forearm, hip, or proximal
humerus fracture).21-23 The development of the FRAX tool has
been advocated by several organizations,7-9 24 supported in part
by funding from the pharmaceutical industry,25-27 which have
advocated the use of FRAX in clinical decision making to
identify high risk candidates for drug treatment to prevent
fracture. This has promoted a shift in treatment approach in
many practice settings from one based primarily onmeasurement
of bone mineral density to an approach based on absolute risk
of fracture.
Use of FRAX in clinical practice demands a consideration of
the probability of fracture at which to intervene.28 On the basis
of a cost effectiveness analysis,29 the NOF in 2010 recommended
FRAX intervention thresholds of 3% for hip fracture and 20%
for major osteoporotic fracture as cut points for starting drug
treatment in US adults aged 50 years and older. However, a
critical unproved assumption in this analysis is that drug
treatment reduces risk of clinical fractures by 35% regardless
of bone mineral density or the presence of existing vertebral
fractures. Despite the controversies in identifying osteoporosis
in men and lack of data on the efficacy of treatment in
preventing clinical fracture events in populations other than
postmenopausal women with osteoporosis as defined by WHO
criteria or with existing vertebral fractures, current US treatment
guidelines recommend starting drug treatment to prevent fracture
in men with a history of hip or vertebral fracture, men with male
specific bone mineral density T scores at or below –2.5, and
men with a male specific bone mineral density T score between
–1.0 and –2.5 who are at or above NOF derived FRAX
intervention thresholds.
We used data collected in 5880 untreated, community dwelling
US men aged 65 years or above enrolled in the prospective
Osteoporotic Fractures in Men (MrOS) study to determine the
incremental effects of broadening the definition of osteoporosis
and use of NOF derived FRAX intervention thresholds on the
proportion of older men identified as candidates for drug
treatment for fracture prevention. We also compared observed
and predicted 10 year fracture probabilities within distinct




From 2000 through 2002, 5994 men who were aged at least 65
years were recruited for participation in the baseline examination
of the Osteoporotic Fractures in Men (MrOS) study.30 31 The
enrollment criteria were designed to recruit a cohort that
represented the characteristics of community dwelling older
men residing in the United States. Men were recruited from
population based listings in six regions (Birmingham, Alabama;
the Monongahela Valley near Pittsburgh, Pennsylvania;
Minneapolis, Minnesota; Palo Alto, California; San Diego,
California; and Portland, Oregon). Men with a history of
bilateral hip replacement, men whowere unable to walk without
the assistance of another person, and men with a medical
condition (in the judgment of the investigator) that would result
in imminent death were excluded. The cohort for this analysis
comprised the 5880 men not taking bisphosphonates at the
baseline examination with hip and spine bone mineral density
measurements, assessment of FRAX clinical risk factors, and
incident fracture ascertainment during 10 years of follow-up.
Clinical risk factors and bonemineral density
Participants were asked at the baseline examination about
race/ethnicity, history of fracture since the age of 50, diagnosis
by a physician of rheumatoid arthritis, parental history of hip
fracture, smoking status, and alcohol intake. Participants were
asked to bring all drug containers used within the preceding 30
days with them to the clinic visit. Drugs were identified and
recorded by the clinic staff, and the information was stored in
an electronic drugs inventory database.32
Measurements of body weight and height were used to calculate
a standard bodymass index. Bone mineral density of the lumbar
spine and total hip including the femoral neck subregion was
measured using dual energy x ray absorptiometry (QDR 4500W,
Hologic,Waltham,MA).31 33As recommended byWHO,6 female
specific T scores at the femoral neck were calculated on the
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basis of the mean and standard deviation obtained from the third
National Health and Nutrition Examination Survey (NHANES
III) white female reference population aged 20-29 years.34 35 A
female specific T score at the femoral neck of –2.5 or below
corresponds to an absolute value of 0.558 g/cm2 or lower. As
recommended by US professional societies including the
NOF,7-9 36 male specific T scores at the femoral neck and total
hip were calculated on the basis of means and standard
deviations obtained from the NHANES III white male reference
population aged 20-29 years,35 and male specific T scores at the
lumbar spine were calculated on the basis of the mean and
standard deviation obtained from the densitometer
manufacturer’s reference database for 30 year old white men.37
A male specific T score of –2.5 or below, as referenced in the
US treatment guidelines, corresponds to an absolute value of
0.592 g/cm2 or lower at the femoral neck, 0.681g/cm2 or lower
at the total hip, or 0.816 g/cm2 or lower at the total lumbar spine
(lumbar vertebra 1-4).
Information on bisphosphonate use (any use within the previous
30 days) was also collected during the 10 year follow-up period
at the following time points: first interim questionnaire (mean
2.0 (SD 0.2) years after baseline examination), first sleep
examination (3.4 (0.5) years), second examination (4.6 (0.4)
years), third examination (6.9 (0.4) years), second interim
questionnaire (8.9 (0.4) years), and second sleep examination
(9.9 (0.8) years).
FRAX tool and 10 year predicted fracture
probabilities
The FRAXweb based tool is publicly available and can be used
for free by providers and patients. For example, when a provider
sees a patient, the provider or a designated staff member can
enter the FRAX clinical risk factor values (components) into
the web based tool, which instantly calculates the 10 year
predicted probabilities of hip fracture and major osteoporotic
fracture (defined by FRAX as hip, clinical vertebral, wrist, or
proximal humerus fracture). However, the specific equations
and algorithms developed by the WHO Collaborating Centre
for Metabolic Bone Disease, University of Sheffield, UK that
generate predicted FRAX fracture probabilities to make
calculation of the FRAX probabilities for all individuals in a
large population feasible have not been published. Thus, to
calculate the US FRAX 10 year predicted probabilities of hip
and major osteoporotic fracture for all 5800 men in this study,
we transmitted data for each participant on FRAX clinical risk
factors (age, sex, race/ethnicity, body mass index, history of
fracture, parental history of hip fracture, smoking and alcohol
consumption, use of oral glucocorticoids, and history of
rheumatoid arthritis, and femoral neck bone mineral density
data (absolute value in g/cm2)) in a confidential and secure
manner to the WHO center, where the probabilities were
computed using FRAX models with bone mineral density
(version 3.3).
If data were missing on any of the clinical characteristics (other
than age, race/ethnicity, body mass index, and bone mineral
density, for which none of the 5880 men had missing data), we
used the default (no) value, as is recommended by the WHO
center.21 For example, if smoking status was missing for a
participant, we classified the participant as a non-smoker. Data
were 100% complete for all characteristics for 4285 men (73%
of the cohort). By far the most common characteristic for which
data were missing was “parental history of hip fracture,” for
which 1405 (24%) of men reported “don’t know.” Information
on drugs used for the definition of “oral glucocorticoid use”
was missing for 238 (4%) men. Other risk factors had missing
data for nine or fewer men.
Ascertainment of fractures
After the baseline examination, we contacted surviving
participants every four months about fractures during the
subsequent 10 year follow-up period. We selected a 10 year
time point to match that specified by the FRAX tool. More than
99% of these follow-up contacts were completed.We confirmed
fractures by review of radiographic reports. Incident fracture
outcomes for this analysis included hip fracture and major
osteoporotic fracture. Follow-up time for the analysis of a given
fracture outcome ended at the date of the first fracture event, at
the date of death, at the date of termination of participation in
theMrOS study, or after 10 years of follow-up. Mean follow-up
for the cohort was 8.6 (SD 2.5) years for hip fracture and 8.5
(2.6) years for major osteoporotic fracture. Of the 5880 men
included in this study, 1634 (27.9%) died and 214 (3.6%)
terminated before reaching 10 years of follow-up.
Statistical analysis
To clearly illustrate the incremental effect of both broadening
the definition of osteoporosis and use of FRAX intervention
thresholds on the proportion of the male population identified
as candidates for treatment, we sequentially applied the WHO
osteoporosis definition, the NOF osteoporosis definition, and
NOF derived FRAX intervention thresholds to the 5880 men,
resulting in four mutually exclusive groups: osteoporosis by
WHO criteria alone; osteoporosis by NOF (but not WHO)
criteria; no osteoporosis but at high risk of fracture (that is, male
specific T score at femoral neck, lumbar spine, and total hip
above –2.5 and predicted 10 year probability of hip fracture at
least 3% or predicted 10 year probability of major osteoporotic
fracture at least 20%); and no osteoporosis and at low risk of
fracture (that is, male specific T score at femoral neck, lumbar
spine, and total hip above –2.5, predicted 10 year probability
of hip fracture less than 3%, and predicted 10 year probability
of major osteoporotic fracture less than 20%).
We calculated observed 10 year probabilities of confirmed
incident hip and major osteoporotic fracture events for each of
the four groups by using cumulative incidence estimation,
accounting for the competing risk of mortality.38We used FRAX
models with femoral neck bone mineral density to estimate
predicted 10 year probabilities for these two outcomes for each
of the four groups.
In the primary analysis for calculating observed fracture
probabilities, we retainedmen starting bisphosphonate treatment
during the follow-up period in the cohort because censoring
them at the time of starting treatment might lead to bias in the
comparison of the observed and predicted fracture probabilities.
To determine the effect of alternative approaches for handling
treatment initiation, we did two sensitivity analyses. The first
calculated observed fracture probabilities with censoring of men
starting bisphosphonates during follow-up at the estimated time
of initiation, and the second calculated observed fracture
probabilities with treatment initiation considered as a competing
risk. For the 426 men who started bisphosphonates during
follow-up, the estimated time of initiation for a given participant
was the midpoint between the last known time point when he
was a non-user and the first time point when bisphosphonate
use was recorded.
As the NOF guideline specifically recommends that drug
treatment should be considered in men with low bone mineral
density but not osteoporosis who are at or above the NOF
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derived intervention threshold, we also did a secondary analysis
limiting the “no osteoporosis but at high fracture risk” group
(n=936) to the 859 men with a male specific bone mineral
density T score between –1.01 and –2.49 and predicted 10 year
probability of hip fracture of at least 3% or predicted 10 year
probability of major osteoporotic fracture of at least 20%.
Finally, we did sensitivity analyses limiting the cohort to the
4285 men with complete data on all clinical characteristics used
in the calculation of FRAX 10 year fracture probabilities.
We used SAS version 9.2 for all analyses except those using
cumulative incidence estimation, for which we used Stata
version 12.1.
Results
Among the cohort of 5880 men, 130 (2.2%) were identified as
having osteoporosis by using WHO criteria based on a female
specific T score of –2.5 or below at the femoral neck. With
subsequent application of the NOF definition, an additional 422
men were identified as having osteoporosis, resulting in a total
prevalence of osteoporosis (based on male specific T score of
–2.5 or below at the femoral neck, total hip, or lumbar spine)
of 9.4%. Of these 422menwhomet NOF (but notWHO) criteria
for osteoporosis, 142 men had a male specific bone mineral
density T score of –2.5 or below at the femoral neck (15
additional men were then subsequently identified owing to a
male specific bone mineral density T score of –2.5 or below at
the total hip, and finally 265 additional men were subsequently
identified owing to a male specific T score of –2.5 or below at
the lumbar spine). With subsequent application of the FRAX
intervention thresholds proposed by the NOF, 936 (15.9%)
additional men without osteoporosis by any criteria were
identified as being at high risk of fracture, raising the total
prevalence of men potentially eligible for drug treatment to
25.3%. Of these 936men, 859 (91.8%) had a male specific bone
mineral density T score between –1.01 and –2.49.
The mean age of men in the overall cohort was 73.6 (range
65-100) years. The table⇓ shows the characteristics of the cohort
according to category of osteoporosis definition and fracture
risk. In particular, among the 936 men without osteoporosis by
WHO or NOF bone mineral density criteria but who were
classified as being at high risk of fracture by virtue of their
FRAX 10 year predicted fracture probabilities, the mean age
and proportion with previous fracture were similar to those
among the 130men with osteoporosis byWHO criteria. Among
this “no osteoporosis but at high fracture risk” group, 934
(99.8%) men had a FRAX 10 year probability of hip fracture
of 3% or higher, but only 65 (6.9%) had a 10 year probability
of major osteoporotic fracture of 20% or higher (63 men met
both FRAX intervention thresholds, 871 men were identified
on the basis of the 3% hip threshold alone, and two men were
identified on the basis of the 20% major osteoporotic fracture
threshold alone). Among the 130 men with osteoporosis by
WHO criteria, 128 (98.5%) had a 10 year probability of hip
fracture of 3% or higher and 30 (23.1%) had a 10 year
probability of major osteoporotic fracture of 20% or higher (30
menmet both FRAX intervention thresholds, 98 were identified
on the basis of the 3% hip threshold alone, none was identified
on the basis of the 20% major osteoporotic fracture threshold
alone, and two met neither FRAX intervention threshold).
During the 10 year follow-up period, 177 (3.0%) men had a hip
fracture. Observed hip fracture probabilities incrementally
decreased across the groups defined by category of osteoporosis
definition and fracture risk, ranging from 20.6% (osteoporosis
byWHO criteria) to 6.8% (osteoporosis by NOF (but notWHO)
criteria), 6.4% (no osteoporosis but at high fracture risk), and
1.5% (no osteoporosis and at low fracture risk) (fig 1⇓). Among
men with osteoporosis, the observed hip fracture probabilities
were greater than the predicted probabilities. In men with
osteoporosis by WHO criteria, the observed probability was
20.6% (95% confidence interval 14.0% to 28.0%) compared
with the FRAX predicted probability of 9.5% (8.2% to 10.7%).
On the other hand, the observed and predicted hip fracture
probabilities were similar among men without osteoporosis,
including those at high and those at low fracture risk.
A total of 429 (7.3%) men had a major osteoporotic fracture
during the 10 year follow-up period. Observed fracture
probabilities ranged from 30.0% (osteoporosis byWHO criteria)
to 18.0% (osteoporosis by NOF (but notWHO) criteria), 12.0%
(no osteoporosis but at high fracture risk), and 4.8% (no
osteoporosis and at low fracture risk) (fig 2⇓). Similar to the
results for hip fracture, observed probabilities of major
osteoporotic fracture were greater than predicted probabilities
among men with osteoporosis, especially those identified by
WHO criteria for whom the observed probability was 30.0%
(22.2% to 38.1%) compared with the FRAX predicted
probability of 17.4% (16.0% to 18.8%). This discrepancy was
again not apparent among men without osteoporosis, including
those at high and those at low fracture risk.
Findings for the comparisons of observed to predicted fracture
probabilities were similar in analyses in which men starting
bisphosphonates during follow-up were censored at the time of
initiation or when initiation of bisphosphonates was considered
as a competing risk. In addition, results were not altered in
analyses in which the group of men without osteoporosis but at
high fracture risk was limited to the 859 men with male specific
bonemineral density T scores between –1.01 and –2.49. Finally,
limiting the cohort to the 4285 men with complete data on all
clinical characteristics used in the calculation of FRAX 10 year
fracture probabilities did not alter our findings for the proportion
of men identified as candidates for drug treatment or results on
observed and predicted fracture probabilities.
Discussion
In this cohort of community dwelling older men living in the
United States, we found that the choice of definition of
osteoporosis and use of National Osteoporosis Foundation
derived FRAX intervention thresholds had major effects on the
proportion of men identified as candidates for drug treatment
to prevent fracture. Expanding the indication for treatment from
menwith osteoporosis defined byWHO criteria to menmeeting
criteria using FRAX intervention thresholds proposed by the
NOF resulted in more than a 10-fold rise in the proportion of
men identified as candidates for drug treatment. Among the 2%
of men identified as having osteoporosis byWHO criteria, who
constitute the group most likely to benefit from drug treatment
to prevent fracture, observed 10 year fracture probabilities were
highest and exceeded FRAX predicted probabilities.
Comparison with other studies
Choice of normative database and number of skeletal sites
considered had a substantial effect on the estimated prevalence
of osteoporosis in older men in this study; a fourfold increase
in the prevalence occurred when we defined osteoporosis by
using NOF (male normative database, three skeletal sites)
instead of WHO (female normative database, one skeletal site)
criteria. These findings are in agreement with most,12 35 39 40 but
not all,11 previous studies. Use of a female derived bone mineral
density T score threshold to define osteoporosis in men is
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supported by a meta-analysis that reported similar relative risks
of fracture per unit decrease in femoral neck bone mineral
density in men and women and similar age adjusted hip fracture
rates in men and women for any given absolute value of femoral
neck bone mineral density.41 Both the NOF and the Endocrine
Society in the United States recommend use of male derived
bone mineral density T score thresholds.7-9 In contrast, the
International Society of Clinical Densitometry recently reversed
its earlier position advocating use of a young male normative
database and recommended that T scores in men be calculated
using a young female normative database.10 36 42
Nearly one out of every six older men in this cohort did not
meet criteria for osteoporosis using even the most liberal
definition but were classified as at high risk of fracture on the
basis of having a 10 year probability of hip or major osteoporotic
fracture at or above FRAX intervention thresholds proposed by
the NOF. Of these, the vast majority (92%) had male specific
bone mineral density T score between –1.01 and –2.49 and
would be candidates for drug treatment according to guidelines
proposed by the NOF and endorsed by other US professional
societies.7-9 36Our finding that the application of NOF treatment
guidelines markedly increased the proportion of older men
identified as candidates for treatment is consistent with those
reported in other studies,43 including a previous analysis of this
cohort.44 Our results expand on these previous cross sectional
reports by clearly showing the incremental effect of broadening
the definition of osteoporosis and use of the FRAX intervention
thresholds recommended by the NOF.
Although basing the treatment decision on a patient’s absolute
risk of fracture is appealing, the efficacy of currently available
treatment in preventing clinical fractures in men and women
without osteoporosis defined by female specific norms or
existing vertebral fractures has not been demonstrated. Previous
trials in men with low bone mineral density have been powered
to detect a change in bone mineral density or a reduction in risk
of new vertebral fractures identified on the basis of radiographs
alone13-17; no trials in men have shown a benefit of treatment in
reducing the risk of clinical fractures. With the exception of one
trial in patients with recent hip fracture,19 evidence of the
efficacy of treatment in reducing clinical fractures is limited to
trials in postmenopausal women with osteoporosis defined by
a female specific bone mineral density T score of –2.5 or below
or with existing radiographic vertebral fractures.18 Systematic
reviews of trials of bisphosphonates in postmenopausal women
have not reported significant reductions in risk of non-vertebral
fractures among women without osteoporosis or existing
vertebral fractures.18 45Although one trial of clodronate reported
efficacy of treatment in reducing clinical fractures (but not hip
fractures) in older women not selected on the basis of bone
mineral density,46 other pivotal trials of alendronate, risedronate,
and denosumab found no benefit of treatment in reducing
clinical fractures among women not selected on the basis of the
WHO definition of osteoporosis (that is, female specific bone
mineral density T score –2.5 or below) or existing vertebral
fractures.47-49 In addition, whether higher estimated FRAX
probabilities identify a subgroup of patients who benefit more
from treatment is unknown. Post hoc analyses of trials in women
of drugs including raloxifene and alendronate have not found
evidence of an interaction between level of FRAX 10 year
fracture probability and treatment assignment for prediction of
risk of fracture events,50 51 although some evidence supported
an interaction in trials of denosumab and clodronate.52 53
Our results indicate that using criteria other than the WHO
definition of osteoporosis to select older men for drug treatment
substantially increases the pool of men labeled as abnormal,
with potential consequences of overdiagnosis and overtreatment.
Because considerable uncertainty exists, randomized trials are
clearly warranted to evaluate the efficacy of treatment in
reducing clinical fractures in older adults without osteoporosis
but at high fracture risk before expanding indications for drug
treatment.
The performance of the FRAX tool has been the subject of
multiple previous studies, including a recent study using data
collected in the Osteoporotic Fractures in Men (MrOS) study
that evaluated the performance of FRAX models with and
without bone mineral density in the overall cohort.54 Findings
suggested that discrimination of men with and without incident
fracture events was improved by addition of bone mineral
density to the calculation, although even the models with bone
mineral density were limited in their ability to predict fracture
events, especially non-hip fractures (the area under the curve
statistic for hip fracture was 0.67 without and 0.77 with bone
mineral density; for major osteoporotic fracture it was 0.63
without and 0.67 with bone mineral density). Results also
indicated suboptimal calibration of FRAX models with bone
mineral density (underestimation of hip fracture probability and
overestimation of major osteoporotic fracture probability). The
observed 10 year cumulative incidence hip fracture probability
was 3.0% compared with a mean 10 year FRAX predicted
probability of 2.3%, and the observed 10 year cumulative
incidence major osteoporotic fracture probability was 6.9%
compared with a mean 10 year FRAX predicted probability of
7.6%.54
Our study determined observed and FRAX predicted
probabilities within mutually exclusive groups of men identified
by osteoporosis status and fracture risk, as US professional
societies have strongly recommended that clinicians consider
both bone mineral density and fracture risk defined using NOF
derived FRAX intervention thresholds in making the critical
decision about whether to recommend drug treatment to a
patient.We found a wide range of observed 10 year probabilities
of hip and major osteoporotic fracture events across these
distinct groups of men. As expected, observed probabilities
were highest amongmenwith osteoporosis as defined byWHO
criteria using a young female specific normative database,
intermediate among men with osteoporosis defined by NOF
(but notWHO) criteria using amale specific normative database,
intermediate among men without osteoporosis but at high
fracture risk, and lowest among men without osteoporosis and
at low fracture risk. Among men with osteoporosis by WHO
criteria, one out of every five had a hip fracture and three out
of every 10 had a major osteoporotic fracture. On the basis of
evidence from randomized trials in women, these men with
osteoporosis defined using a young female specific normative
database are most likely to benefit from drug treatment to
prevent fracture. However, our results indicated that fracture
probabilities as calculated by the FRAX tool in this group of
men underestimated their actual fracture risk. Because the FRAX
tool did not underestimate fracture risk among men without
osteoporosis, differences in predicted fracture probabilities
across groups were smaller than actual observed differences in
fracture probabilities. As patients may be prepared accept a
higher absolute fracture risk than providers are before
considering drug treatment to be justified,55 information about
absolute fracture riskmust be accurately conveyed to the patients
most likely to benefit from treatment. In addition, evidence
suggests that a large discrepancy may exist between NOF
recommended FRAX intervention thresholds and acceptable
intervention thresholds of patients.55
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In addition to FRAX, many other tools for assessing fracture
risk have been developed. A recent systematic review of these
tools identified a total of 48 instruments,56 but only six were
validated more than once in a population based setting with
acceptable methodological quality. None of these six tools
consistently performed better than the others, and simple tools
often did as well as or better than more complex tools including
FRAX. No studies determined the effectiveness of tools in
selecting patients for treatment or reported that a screening
and/or treatment strategy based on a specific tool reduced the
risk of clinical fractures. Thus, randomized trials are needed to
evaluate the comparative effectiveness of strategies based on
fracture risk assessment tools in reducing risk of clinical fracture
events before widespread adoption of these tools into clinical
decision making in the practice setting regarding whether to
recommend drug treatment. In addition, decreasing the societal
burden of fractures among older adults will require effective
interventions beyond available skeletal treatments targeted at
patients with low bone mineral density. Thus, randomized trials
are also warranted to evaluate the efficacy of non-skeletal
interventions (for example, community based fall prevention
strategies) in reducing fracture events.
Strengths and limitations of study
This study has several strengths, including the large, well
characterized cohort with nearly complete long term follow-up
of fracture events. Observed fracture probabilities were adjusted
for the competing risk of mortality.
However, this study has several limitations. The cohort
comprised community dwelling, predominantlywhitemen living
in the United States. Characteristics including status of clinical
risk factors for fracture and hip bone mineral density were in
general similar to those of a population based sample of men
aged 65 years and over enrolled in NHANES III,44 but fewer
men in the MrOS study were current smokers. This may in part
explain the discrepancy between observed and predicted FRAX
fracture probabilities among men with osteoporosis in our
cohort, as smoking is a risk factor for mortality.
Our findings on the effect of using FRAX intervention
thresholds on the proportion of men identified as warranting
drug treatment are limited to the thresholds identified by the
NOF for the United States and do not necessarily apply to
strategies proposed in other countries.57-59 For example, the
National Osteoporosis Guideline Group,58 in collaboration with
other societies in the United Kingdom, recommends using the
FRAX 10 year probability of major osteoporotic fracture
calculated without bone mineral density to assess the need for
bone mineral density testing in an adults aged 50 years and
older; among patients requiring a bone mineral density test, the
re-calculated FRAX 10 year probability of major osteoporotic
fracture with bonemineral density is used to determine whether
drug treatment is warranted. In these guidelines, FRAX
intervention thresholds for bone mineral density testing and for
starting drug treatment vary according to age. To our knowledge,
the implications of using these guidelines on the proportion of
UK adults identified as candidates for drug treatment to prevent
fracture have not been examined. Our findings suggest that use
of a single FRAX intervention threshold based on probability
of major osteoporotic fracture of 20% would identify a much
smaller proportion of older men without evidence of
osteoporosis (by any definition) as warranting drug treatment,
as the vast majority of men in this group in our study were
identified as being eligible for treatment because they met or
exceeded the hip fracture threshold of 3%. However, our
findings also indicate that reliance on the FRAX 20% threshold
alone without consideration of bone mineral density would fail
to identify more than 75% of men with osteoporosis by WHO
criteria.
Although evidence exists showing the efficacy of several drug
treatments in preventing clinical fractures among
postmenopausal women with existing vertebral fractures,60 and
one randomized trial has shown efficacy of zoledronic acid in
preventing symptomatic fractures among patients with recent
hip fracture,19 our study did not specifically look at the effect
of selecting older men for drug treatment on the basis of these
criteria. Because the equations and algorithms that generate the
fracture risk probabilities have not been published for the FRAX
tool, this study could not investigate the relative importance of
individual FRAX clinical risk factors in fracture prediction.
Finally, the absolute number of fracture events in each of the
four groups of men in this study was small, and our findings
should be confirmed using data collected in other long term
prospective studies of older men.
Conclusions and implications
In conclusion, broadening the indication for drug treatment
beyond men with osteoporosis as defined by WHO criteria
resulted in a large increase in the proportion of older community
dwelling men in the United States who were identified as
warranting drug treatment to prevent fracture. Men with
osteoporosis by WHO criteria had observed probabilities of
clinical fracture events that exceeded their FRAX predicted
probabilities. Based on data from trials in women, these men
with osteoporosis by WHO criteria are most likely to benefit
from treatment. As the goal of treatment is to prevent clinical
(symptomatic) fractures, our results in the context of the
available medical literature indicate that treatment should be
offered to men who meet WHO criteria for osteoporosis (that
is, femoral neck bone mineral density of 0.558 g/cm2 or below),
men with existing vertebral fractures, and men with a recent
history of hip fracture. Expanding indications for treatment
beyond this group has unknown value owing to lower observed
fracture probabilities and uncertain benefits of treatment and
would result in overdiagnosis and overtreatment. Randomized
clinical trials are warranted to evaluate the efficacy of drug
treatment in reducing clinical fractures in older men and women
without osteoporosis but at high risk of fracture before a
fundamental change in the strategy used to identify candidates
for drug treatment is adopted.
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What is already known on this topic
The efficacy of drug treatment in preventing clinical (symptomatic) fractures in men is unknown, but treatment in postmenopausal women
with osteoporosis reduces the risk of clinical fractures
Several US professional societies now recommend using cut points of 10 year absolute fracture risk as estimated by the FRAX tool in
making decisions about whether to start drug treatment in adults aged 50 or over
Previous studies have suggested that application of these recommended FRAX intervention thresholds increases the proportion of older
adults identified as candidates for drug treatment
However, the incremental impact of both broadening the definition of osteoporosis and use of FRAX intervention thresholds on the
proportion of older men identified as candidates for drug treatment is uncertain
What this study adds
Depending on the definition of osteoporosis and the FRAX absolute fracture risk cut points applied to the study population, the proportion
of men labeled as abnormal and warranting treatment varied from 2% up to 25%
Among men identified as having osteoporosis according to a stringent definition, who comprised 2% of the study population, actual
observed fracture probabilities during 10 years of follow-up were highest and exceeded FRAX predicted fracture probabilities
Based on results of randomized trials in women, these men are most likely to benefit from drug treatment to prevent fracture
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Table 1| Characteristics of 5880 participants according to definition of osteoporosis and fracture risk category*. Values are numbers
(percentages) unless stated otherwise
No osteoporosis by WHO or NOF criteriaOsteoporosis by











72.5 (5.5)77.9 (5.0)74.3 (6.2)77.1 (6.4)73.6 (5.9)Mean (SD) age, years
Age group, years:
1570 (36)42 (4)116 (27)19 (15)1747 (30)65-69
1364 (31)184 (20)105 (25)25 (19)1678 (29)70-74
931 (21)339 (36)112 (27)37 (28)1419 (24)75-79
527 (12)371 (40)89 (21)49 (38)1036 (18)≥80
3854 (88)908 (97)377 (89)118 (91)5257 (89)White ethnicity
Mean (SD) bone mineral density,
g/cm2:
1.22 (0.24)1.12 (0.19)0.88 (0.13)0.94 (0.19)1.17 (0.25)Lumbar spine
0.83 (0.11)0.69 (0.07)0.65 (0.08)0.52 (0.04)0.79 (0.13)Femoral neck
1.00 (0.12)0.87 (0.09)0.80 (0.09)0.68 (0.08)0.96 (0.14)Total hip
27.9 (3.8)26.2 (3.1)26.1 (4.3)24.6 (3.2)27.4 (3.8)Mean (SD) body mass index,
kg/m2
146 (3)34 (4)16 (4)9 (7)205 (3)Current smoker
162 (4)58 (6)14 (3)3 (2)237 (4)≥3 alcoholic drinks/day
745 (17)381 (41)121 (29)52 (40)1299 (22)Any fracture since age 50
297 (7)110 (12)57 (14)13 (10)477 (8)Oral corticosteroid use
193 (4)82 (9)21 (5)8 (6)304 (5)Rheumatoid arthritis
305 (7)355 (38)62 (15)21 (16)743 (13)Parental history of hip fracture
0 (0)934 (~100)237 (56)128 (98)1299 (22)FRAX 10 year probability of hip
fracture ≥3%
0 (0)65 (7)27 (6)30 (23)122 (2)FRAX 10 year probability of major
osteoporotic fracture ≥20%
161 (4)91 (10)134 (32)40 (31)426 (7)Started bisphosphonate treatment
during follow-up
64 (1)59 (6)28 (7)26 (20)177 (3)Incident hip fracture
206 (5)111 (12)74 (18)38 (29)429 (7)Incident major osteoporotic
fracture
1247 (28)430 (46)151 (36)55 (42)1883 (32)Died during follow-up
All characteristics assessed at baseline except for incident hip fracture, incident major osteoporotic fracture, and death.
*Fracture risk calculated using models with femoral neck bone mineral density (BMD).
†World Health Organization definition of osteoporosis based on use of female specific T score of –2.5 or below at femoral neck (that is, femoral neck BMD ≤0.558
g/cm2).
‡National Osteoporosis Foundation definition of osteoporosis based on use of male specific T score of –2.5 or below at femoral neck, total hip, or lumbar spine;
this group (osteoporosis by NOF but not WHO criteria) includes men with femoral neck BMD 0.558-0.592 g/cm2, total hip BMD ≤0.681 g/cm2, or total lumbar spine
BMD ≤0.816 g/cm2.
§High fracture risk as defined by FRAX (with BMD) 10 year probabilities of hip fracture ≥3% or major osteoporotic fracture ≥20%; low fracture risk as defined by
FRAX (with BMD) 10 year probabilities of hip fracture <3% and major osteoporotic fracture <20%.
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Fig 1 Observed versus predicted 10 year probability of hip fracture according to definition and fracture risk. 26 hip fractures
occurred among 130 men with osteoporosis by WHO criteria alone, 28 among 422 men with osteoporosis by National
Osteoporosis Foundation (NOF) (but not WHO) criteria, 59 among 936 men without osteoporosis but at high risk of fracture,
and 64 among 4392 men without osteoporosis and at low risk of fracture
Fig 2 Observed versus predicted 10 year probability of major osteoporotic fracture according to definition and fracture risk.
38 major osteoporotic fractures occurred among 130 men with osteoporosis by WHO criteria alone, 74 among 422 men
with osteoporosis by National Osteoporosis Foundation (NOF) (but not WHO) criteria, 111 among 936 men without
osteoporosis but at high risk of fracture, and 206 among 4392 men without osteoporosis but at low risk of fracture
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